Reconstituted complexes of mycobacterial HSP70 and EBV LMP2A-derived peptides elicit peptide-specific cytotoxic T lymphocyte responses and anti-tumor immunity
Abstract Epstein–Barr virus (EBV) latent membrane protein 2A (LMP2A) is a subdominant antigen expressed in EBV-associated malignancies, such as Hodgkin's diseases (HD) and nasopharyngeal carcinoma. A large number of previous studies have described LMP2A as an ideal target antigen in immunothera...
Saved in:
Published in | Vaccine Vol. 29; no. 43; pp. 7414 - 7423 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Kidlington
Elsevier Ltd
06.10.2011
Elsevier Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract Epstein–Barr virus (EBV) latent membrane protein 2A (LMP2A) is a subdominant antigen expressed in EBV-associated malignancies, such as Hodgkin's diseases (HD) and nasopharyngeal carcinoma. A large number of previous studies have described LMP2A as an ideal target antigen in immunotherapy of EBV-related diseases, while limited successes have been achieved in clinical trials. Mycobacterium tuberculosis heat shock protein 70 (MtHsp70) is known as an effective molecular adjuvant for protein- or epitope-based vaccines. In the present study, we reconstituted two chaperone complexes of MtHsp70 and LMP2A-derived peptides (LMP2A356–364 FLYALALLL and LMP2A426–434 CLGGLLTMV) in vitro . We then investigated LMP2A-specific immune responses induced by reconstituted complexes of MtHsp70 and LMP2A-peptides using both EBV infected healthy donor PBMCs and HLA-A2.1 transgenic mouse models. We found that reconstituted complexes of MtHsp70 and LMP2A-peptides significantly elicit LMP2A-specific IFN-γ-producing cells and rousted cytotoxic T lymphocytes (CTLs) in vitro and in vivo . In addition, LMP2A-specific immune responses induced by the reconstituted complexes of MtHsp70 and LMP2A-peptides mediated potently protective activity as well as therapeutic efficacy against LMP2A-expressed tumor challenge in mouse models. These studies provide new insights for the development of novel LMP2A-based vaccines against EBV-associated malignancies. |
---|---|
AbstractList | Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A) is a subdominant antigen expressed in EBV-associated malignancies, such as Hodgkin's diseases (HD) and nasopharyngeal carcinoma. A large number of previous studies have described LMP2A as an ideal target antigen in immunotherapy of EBV-related diseases, while limited successes have been achieved in clinical trials. Mycobacterium tuberculosis heat shock protein 70 (MtHsp70) is known as an effective molecular adjuvant for protein- or epitope-based vaccines. In the present study, we reconstituted two chaperone complexes of MtHsp70 and LMP2A-derived peptides (LMP2A(356-364) FLYALALLL and LMP2A(426-434) CLGGLLTMV) in vitro. We then investigated LMP2A-specific immune responses induced by reconstituted complexes of MtHsp70 and LMP2A-peptides using both EBV infected healthy donor PBMCs and HLA-A2.1 transgenic mouse models. We found that reconstituted complexes of MtHsp70 and LMP2A-peptides significantly elicit LMP2A-specific IFN-γ-producing cells and rousted cytotoxic T lymphocytes (CTLs) in vitro and in vivo. In addition, LMP2A-specific immune responses induced by the reconstituted complexes of MtHsp70 and LMP2A-peptides mediated potently protective activity as well as therapeutic efficacy against LMP2A-expressed tumor challenge in mouse models. These studies provide new insights for the development of novel LMP2A-based vaccines against EBV-associated malignancies. Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A) is a subdominant antigen expressed in EBV-associated malignancies, such as Hodgkin's diseases (HD) and nasopharyngeal carcinoma. A large number of previous studies have described LMP2A as an ideal target antigen in immunotherapy of EBV-related diseases, while limited successes have been achieved in clinical trials.Mycobacterium tuberculosisheat shock protein 70 (MtHsp70) is known as an effective molecular adjuvant for protein- or epitope-based vaccines. In the present study, we reconstituted two chaperone complexes of MtHsp70 and LMP2A-derived peptides (LMP2A356-364FLYALALLL and LMP2A426-434CLGGLLTMV)in vitro. We then investigated LMP2A-specific immune responses induced by reconstituted complexes of MtHsp70 and LMP2A-peptides using both EBV infected healthy donor PBMCs and HLA-A2.1 transgenic mouse models. We found that reconstituted complexes of MtHsp70 and LMP2A-peptides significantly elicit LMP2A-specific IFN-γ-producing cells and rousted cytotoxic T lymphocytes (CTLs)in vitroandin vivo. In addition, LMP2A-specific immune responses induced by the reconstituted complexes of MtHsp70 and LMP2A-peptides mediated potently protective activity as well as therapeutic efficacy against LMP2A-expressed tumor challenge in mouse models. These studies provide new insights for the development of novel LMP2A-based vaccines against EBV-associated malignancies. Epstein–Barr virus (EBV) latent membrane protein 2A (LMP2A) is a subdominant antigen expressed in EBV-associated malignancies, such as Hodgkin's diseases (HD) and nasopharyngeal carcinoma. A large number of previous studies have described LMP2A as an ideal target antigen in immunotherapy of EBV-related diseases, while limited successes have been achieved in clinical trials. Mycobacterium tuberculosis heat shock protein 70 (MtHsp70) is known as an effective molecular adjuvant for protein- or epitope-based vaccines. In the present study, we reconstituted two chaperone complexes of MtHsp70 and LMP2A-derived peptides (LMP2A356–364 FLYALALLL and LMP2A426–434 CLGGLLTMV) in vitro. We then investigated LMP2A-specific immune responses induced by reconstituted complexes of MtHsp70 and LMP2A-peptides using both EBV infected healthy donor PBMCs and HLA-A2.1 transgenic mouse models. We found that reconstituted complexes of MtHsp70 and LMP2A-peptides significantly elicit LMP2A-specific IFN-γ-producing cells and rousted cytotoxic T lymphocytes (CTLs) in vitro and in vivo. In addition, LMP2A-specific immune responses induced by the reconstituted complexes of MtHsp70 and LMP2A-peptides mediated potently protective activity as well as therapeutic efficacy against LMP2A-expressed tumor challenge in mouse models. These studies provide new insights for the development of novel LMP2A-based vaccines against EBV-associated malignancies. Epstein–Barr virus (EBV) latent membrane protein 2A (LMP2A) is a subdominant antigen expressed in EBV-associated malignancies, such as Hodgkin's diseases (HD) and nasopharyngeal carcinoma. A large number of previous studies have described LMP2A as an ideal target antigen in immunotherapy of EBV-related diseases, while limited successes have been achieved in clinical trials. Mycobacterium tuberculosis heat shock protein 70 (MtHsp70) is known as an effective molecular adjuvant for protein- or epitope-based vaccines. In the present study, we reconstituted two chaperone complexes of MtHsp70 and LMP2A-derived peptides (LMP2A₃₅₆–₃₆₄ FLYALALLL and LMP2A₄₂₆–₄₃₄ CLGGLLTMV) in vitro. We then investigated LMP2A-specific immune responses induced by reconstituted complexes of MtHsp70 and LMP2A-peptides using both EBV infected healthy donor PBMCs and HLA-A2.1 transgenic mouse models. We found that reconstituted complexes of MtHsp70 and LMP2A-peptides significantly elicit LMP2A-specific IFN-γ-producing cells and rousted cytotoxic T lymphocytes (CTLs) in vitro and in vivo. In addition, LMP2A-specific immune responses induced by the reconstituted complexes of MtHsp70 and LMP2A-peptides mediated potently protective activity as well as therapeutic efficacy against LMP2A-expressed tumor challenge in mouse models. These studies provide new insights for the development of novel LMP2A-based vaccines against EBV-associated malignancies. Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A) is a subdominant antigen expressed in EBV-associated malignancies, such as Hodgkin's diseases (HD) and nasopharyngeal carcinoma. A large number of previous studies have described LMP2A as an ideal target antigen in immunotherapy of EBV-related diseases, while limited successes have been achieved in clinical trials. Mycobacterium tuberculosis heat shock protein 70 (MtHsp70) is known as an effective molecular adjuvant for protein- or epitope-based vaccines. In the present study, we reconstituted two chaperone complexes of MtHsp70 and LMP2A-derived peptides (LMP2A sub(356-364 FLYALALLL and LMP2A) sub(4)26-434 CLGGLLTMV) in vitro. We then investigated LMP2A-specific immune responses induced by reconstituted complexes of MtHsp70 and LMP2A-peptides using both EBV infected healthy donor PBMCs and HLA-A2.1 transgenic mouse models. We found that reconstituted complexes of MtHsp70 and LMP2A-peptides significantly elicit LMP2A-specific IFN-[gamma]-producing cells and rousted cytotoxic T lymphocytes (CTLs) in vitro and in vivo. In addition, LMP2A-specific immune responses induced by the reconstituted complexes of MtHsp70 and LMP2A-peptides mediated potently protective activity as well as therapeutic efficacy against LMP2A-expressed tumor challenge in mouse models. These studies provide new insights for the development of novel LMP2A-based vaccines against EBV-associated malignancies. Abstract Epstein–Barr virus (EBV) latent membrane protein 2A (LMP2A) is a subdominant antigen expressed in EBV-associated malignancies, such as Hodgkin's diseases (HD) and nasopharyngeal carcinoma. A large number of previous studies have described LMP2A as an ideal target antigen in immunotherapy of EBV-related diseases, while limited successes have been achieved in clinical trials. Mycobacterium tuberculosis heat shock protein 70 (MtHsp70) is known as an effective molecular adjuvant for protein- or epitope-based vaccines. In the present study, we reconstituted two chaperone complexes of MtHsp70 and LMP2A-derived peptides (LMP2A356–364 FLYALALLL and LMP2A426–434 CLGGLLTMV) in vitro . We then investigated LMP2A-specific immune responses induced by reconstituted complexes of MtHsp70 and LMP2A-peptides using both EBV infected healthy donor PBMCs and HLA-A2.1 transgenic mouse models. We found that reconstituted complexes of MtHsp70 and LMP2A-peptides significantly elicit LMP2A-specific IFN-γ-producing cells and rousted cytotoxic T lymphocytes (CTLs) in vitro and in vivo . In addition, LMP2A-specific immune responses induced by the reconstituted complexes of MtHsp70 and LMP2A-peptides mediated potently protective activity as well as therapeutic efficacy against LMP2A-expressed tumor challenge in mouse models. These studies provide new insights for the development of novel LMP2A-based vaccines against EBV-associated malignancies. |
Author | Liu, Genyan Yao, Kun Zhou, Feng Li, Linyun Peng, Guangyong Wang, Bing Chen, Yun Chi, Jing |
Author_xml | – sequence: 1 fullname: Liu, Genyan – sequence: 2 fullname: Yao, Kun – sequence: 3 fullname: Wang, Bing – sequence: 4 fullname: Zhou, Feng – sequence: 5 fullname: Chen, Yun – sequence: 6 fullname: Li, Linyun – sequence: 7 fullname: Chi, Jing – sequence: 8 fullname: Peng, Guangyong |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24686689$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21807054$$D View this record in MEDLINE/PubMed |
BookMark | eNqNks1u1DAUhSNURKeFRwAiIcQqw7WdH2dTVKpCkQZRMS3qzvI41-AhiYPtjDovw7PiaKZU6gZW_vvO8b0-PkoOettjkjwnMCdAyrfr-UYqZXqcUyBkDtUcSvYomRFesYwWhB8kM6BlnuUEbg6TI-_XAFAwUj9JDinhUEGRz5LfX1HZ3gcTxoBNqmw3tHiLPrU67bbKrqQK6Ixs04vlZQWp7Jv0_P23dPH5kp5mTTzaRNmAQzBNVGFrlAl368wPqIw2KlXbYIO9jbOrtN12ww8bdzB16Id4exROvrIPJgtjZ11qum7sTdg-TR5r2Xp8th-Pk-sP51dnF9niy8dPZ6eLTBWMhUwjkJysgFNeEsoL5KWqgBGqWMM15gwZSMbjhtYay5pIWWOtqa4KCTTX7Dh5s_MdnP01og-iM15h28oe7egFr2vCOC3r_yBLVheEVZF89YBc29H1sQ1B8ppDXeUwUcWOUs5671CLwZlOuq0gIKakxVrskxZT0gIqEZOOuhd793HVYfNXdRdtBF7vAemVbLWTvTL-nstLXpZ8aujljtPSCvndReZ6GW8qIL4pJXURiXc7AmMCG4NOeGWwV9gYhyqIxpp_FnvywEG1pjexrJ-4RX__LsJTAWI5fdzp35LoSYDfsD_td-qU |
CODEN | VACCDE |
CitedBy_id | crossref_primary_10_3390_vaccines9111290 crossref_primary_10_1080_21645515_2019_1670593 crossref_primary_10_1007_s10695_012_9724_z crossref_primary_10_3389_fcimb_2018_00095 crossref_primary_10_1186_1479_5876_10_96 crossref_primary_10_3389_fonc_2024_1388999 crossref_primary_10_3389_fimmu_2021_677027 |
Cites_doi | 10.1093/jac/dkg306 10.1016/j.tibs.2006.01.006 10.1182/blood-2004-07-2975 10.1200/JCO.2005.02.6195 10.1146/annurev.immunol.15.1.405 10.1128/JVI.80.2.883-890.2006 10.1016/S0140-6736(02)09672-1 10.1097/00002371-200407000-00008 10.1038/cmi.2008.45 10.1084/jem.186.8.1315 10.1084/jem.191.2.403 10.1016/S0002-9440(10)61130-3 10.4049/jimmunol.165.1.573 10.1128/JVI.01409-07 10.1038/nrd2224 10.1182/blood-2007-05-091280 10.2174/156652407780831575 10.1128/JVI.77.4.2757-2761.2003 10.1074/jbc.M704129200 10.4049/jimmunol.158.7.3325 10.1182/blood-2003-08-2828 10.1016/S0140-6736(05)66698-6 10.1016/j.anl.2006.05.019 10.1002/ijc.10309 10.1002/path.1569 10.1038/cmi.2009.13 10.1016/j.vaccine.2008.06.092 10.1128/JVI.67.12.7428-7435.1993 10.1126/science.278.5335.117 10.1128/JVI.78.2.768-778.2004 10.1038/cmi.2009.54 10.1200/JCO.2007.11.9941 10.1128/CVI.00029-07 10.1128/JVI.73.1.334-342.1999 10.1016/S0140-6736(95)91150-2 10.1016/S1471-4906(01)01896-8 10.1016/S0264-410X(01)00085-8 10.4049/jimmunol.180.5.3122 10.1016/j.addr.2005.01.002 10.1182/blood.V92.7.2477 10.1517/14712590802614538 10.1128/JVI.70.8.5357-5362.1996 |
ContentType | Journal Article |
Copyright | Elsevier Ltd 2011 Elsevier Ltd 2015 INIST-CNRS Copyright © 2011 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Oct 6, 2011 |
Copyright_xml | – notice: Elsevier Ltd – notice: 2011 Elsevier Ltd – notice: 2015 INIST-CNRS – notice: Copyright © 2011 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Oct 6, 2011 |
DBID | FBQ IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PQEST PQQKQ PQUKI Q9U 7X8 |
DOI | 10.1016/j.vaccine.2011.07.063 |
DatabaseName | AGRIS Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) ProQuest Nursing and Allied Health Journals Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni Edition) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Biological Science Collection ProQuest Consumer Health Database Health & Medical Collection (Alumni Edition) Healthcare Administration Database Medical Database Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Research Library Prep ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) Environmental Sciences and Pollution Management ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Central Basic ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) Immunology Abstracts ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE Research Library Prep AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database – sequence: 4 dbid: FBQ name: AGRIS url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1873-2518 |
EndPage | 7423 |
ExternalDocumentID | 3218552921 10_1016_j_vaccine_2011_07_063 21807054 24686689 US201500142195 S0264410X1101108X 1_s2_0_S0264410X1101108X |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 0SF 123 1B1 1P~ 1RT 1~. 1~5 29Q 3V. 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AACTN AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AAXKI AAXUO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ABXDB ACDAQ ACGFO ACGFS ACIUM ACPRK ACRLP ADBBV ADEZE ADFRT ADMUD ADVLN AEBSH AEFWE AEKER AENEX AEVXI AEXOQ AFCTW AFJKZ AFKRA AFKWA AFRAH AFRHN AFTJW AFXIZ AGEKW AGGSO AGHFR AGUBO AGYEJ AHHHB AHMBA AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALIPV ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AQUVI ASPBG AVWKF AXJTR AZFZN AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HEJ HLV HMG HMK HMO HVGLF HX~ HZ~ IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PQQKQ PROAC PSQYO Q38 R2- RIG ROL RPZ SAB SAE SCC SDF SDG SDP SES SEW SIN SNL SPCBC SSH SSI SSZ SVS T5K UV1 WH7 WOW WUQ XPP Z5R ZGI ZXP ~G- AAIAV ABLVK ABYKQ AESVU AJBFU EFLBG HMCUK LCYCR QYZTP UKHRP ABPIF ABPTK FBQ IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PQEST PQUKI Q9U 7X8 |
ID | FETCH-LOGICAL-c533t-fe0141b082861285e86c70312c3d8fe43e30a38312fffe691aa9e9f2f75a024f3 |
IEDL.DBID | 8C1 |
ISSN | 0264-410X |
IngestDate | Thu Oct 24 23:07:59 EDT 2024 Fri Oct 25 05:21:53 EDT 2024 Thu Oct 10 21:02:53 EDT 2024 Thu Sep 26 16:15:36 EDT 2024 Sat Sep 28 08:34:05 EDT 2024 Sun Oct 22 16:08:31 EDT 2023 Wed Dec 27 19:02:04 EST 2023 Fri Feb 23 02:31:55 EST 2024 Tue Oct 15 22:55:51 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 43 |
Keywords | Heat shock protein 70 Adjuvant Latent membrane protein 2A Immunotherapy Epstein–Barr virus Gammaherpesvirinae Mycobacterium Membrane protein Peptides Herpesviridae Cytotoxicity Epstein Barr virus Malignant tumor Virus Mycobacteriales Immunological adjuvant T-Lymphocyte Heat shock protein Mycobacteriaceae Bacteria Actinomycetes Epstein-Barr virus Cytotoxic T lymphocyte Cancer |
Language | English |
License | CC BY 4.0 Copyright © 2011 Elsevier Ltd. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c533t-fe0141b082861285e86c70312c3d8fe43e30a38312fffe691aa9e9f2f75a024f3 |
Notes | http://dx.doi.org/10.1016/j.vaccine.2011.07.063 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
PMID | 21807054 |
PQID | 1498097407 |
PQPubID | 105530 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_899138269 proquest_miscellaneous_896395137 proquest_journals_1498097407 crossref_primary_10_1016_j_vaccine_2011_07_063 pubmed_primary_21807054 pascalfrancis_primary_24686689 fao_agris_US201500142195 elsevier_sciencedirect_doi_10_1016_j_vaccine_2011_07_063 elsevier_clinicalkeyesjournals_1_s2_0_S0264410X1101108X |
PublicationCentury | 2000 |
PublicationDate | 2011-10-06 |
PublicationDateYYYYMMDD | 2011-10-06 |
PublicationDate_xml | – month: 10 year: 2011 text: 2011-10-06 day: 06 |
PublicationDecade | 2010 |
PublicationPlace | Kidlington |
PublicationPlace_xml | – name: Kidlington – name: Netherlands |
PublicationTitle | Vaccine |
PublicationTitleAlternate | Vaccine |
PublicationYear | 2011 |
Publisher | Elsevier Ltd Elsevier Elsevier Limited |
Publisher_xml | – name: Elsevier Ltd – name: Elsevier – name: Elsevier Limited |
References | Taylor, Haigh, Gudgeon, Phelps, Lee, Steven (bib0110) 2004; 78 Haque, Wilkie, Taylor, Amlot, Murad, Iley (bib0010) 2002; 360 Blachere, Li, Chandawarkar, Suto, Jaikaria, Basu (bib0155) 1997; 186 Bollard, Gottschalk, Leen, Weiss, Straathof, Carrum (bib0140) 2007; 110 Rickinson, Moss (bib0050) 1997; 15 Straathof, Bollard, Popat, Huls, Lopez, Morriss (bib0090) 2005; 105 Cancer IAfRo (bib0005) 1997; 70 Wang, Yao, Liu, Xie, Zhou, Chen (bib0055) 2009; 6 Bollard, Straathof, Huls, Leen, Lacuesta, Davis (bib0040) 2004; 27 Lautscham, Haigh, Mayrhofer, Taylor, Croom-Carter, Leese (bib0070) 2003; 77 Grange, Bottasso, Stanford, Stanford (bib0195) 2008; 26 Testori, Richards, Whitman, Mann, Lutzky, Camacho (bib0205) 2008; 26 Bendz, Ruhland, Pandya, Hainzl, Riegelsberger, Brauchle (bib0160) 2007; 282 Liu, Wu, Rowse, Emtage (bib0120) 2007; 14 Lee, Thomas, Murray, Khanim, Kaur, Young (bib0060) 1993; 67 Wan, Zhou, Chen, An, Chen, Zhang (bib0165) 2004; 103 Heussinger, Buttner, Ott, Brachtel, Pilch, Kremmer (bib0025) 2004; 203 Bharadwaj, Sherritt, Khanna, Moss (bib0095) 2001; 19 Elliott, Suhrbier, Miles, Lawrence, Pye, Le (bib0175) 2008; 82 Huang, Richmond, Suzue, Eisen, Young (bib0125) 2000; 191 Calderwood, Khaleque, Sawyer, Ciocca (bib0215) 2006; 31 Murray, Constandinou, Crocker, Young, Ambinder (bib0150) 1998; 92 Lin, Lo, Lee, Ren, Hwang, Cheng (bib0100) 2002; 62 Wong, Bos, Sherman (bib0190) 2008; 180 Sun, Yao, Chen, Zhou (bib0035) 2004; 117 Purcell, McCluskey, Rossjohn (bib0105) 2007; 6 Comoli, Pedrazzoli, Maccario, Basso, Carminati, Labirio (bib0145) 2005; 23 Wang (bib0180) 2001; 22 Ito, Kondo, Demachi-Okamura, Akatsuka, Tsujimura, Tanimoto (bib0220) 2006; 80 Meij, Leen, Rickinson, Verkoeijen, Vervoort, Bloemena (bib0085) 2002; 99 Walker, Keeble, Colaco (bib0115) 2007; 7 Xu, Yao, Yu, Chen, Lu, Sun (bib0030) 2006; 33 Lee, Chan, Cheung, Thomas, CroomCarter, Dawson (bib0065) 2000; 165 Redchenko, Rickinson (bib0135) 1999; 73 Mittendorf, Holmes, Murray, von Hofe, Peoples (bib0185) 2009; 9 Tamura, Peng, Liu, Daou, Srivastava (bib0200) 1997; 278 Rooney, Smith, Ng, Loftin, Li, Krance (bib0015) 1995; 345 Liu, Yao, Wang, Chen, Zhou, Guo (bib0130) 2009; 6 Lee, Tierney, Thomas, Brooks, Rickinson (bib0075) 1997; 158 Khanna, Burrows, Moss, Silins (bib0080) 1996; 70 Rolland (bib0170) 2005; 57 Tao, Yang, Huang, Swinnen, Ambinder (bib0225) 2002; 160 Chen, Yao, Wang, Qing, Liu (bib0020) 2008; 5 Swanson-Mungerson, Ikeda, Lev, Longnecker, Portis (bib0045) 2003; 52 Wei, Sham (bib0210) 2005; 365 Rooney (10.1016/j.vaccine.2011.07.063_bib0015) 1995; 345 Testori (10.1016/j.vaccine.2011.07.063_bib0205) 2008; 26 Swanson-Mungerson (10.1016/j.vaccine.2011.07.063_bib0045) 2003; 52 Wan (10.1016/j.vaccine.2011.07.063_bib0165) 2004; 103 Mittendorf (10.1016/j.vaccine.2011.07.063_bib0185) 2009; 9 Bharadwaj (10.1016/j.vaccine.2011.07.063_bib0095) 2001; 19 Huang (10.1016/j.vaccine.2011.07.063_bib0125) 2000; 191 Liu (10.1016/j.vaccine.2011.07.063_bib0120) 2007; 14 Heussinger (10.1016/j.vaccine.2011.07.063_bib0025) 2004; 203 Lee (10.1016/j.vaccine.2011.07.063_bib0075) 1997; 158 Xu (10.1016/j.vaccine.2011.07.063_bib0030) 2006; 33 Taylor (10.1016/j.vaccine.2011.07.063_bib0110) 2004; 78 Bendz (10.1016/j.vaccine.2011.07.063_bib0160) 2007; 282 Khanna (10.1016/j.vaccine.2011.07.063_bib0080) 1996; 70 Cancer IAfRo (10.1016/j.vaccine.2011.07.063_bib0005) 1997; 70 Lee (10.1016/j.vaccine.2011.07.063_bib0065) 2000; 165 Liu (10.1016/j.vaccine.2011.07.063_bib0130) 2009; 6 Haque (10.1016/j.vaccine.2011.07.063_bib0010) 2002; 360 Lee (10.1016/j.vaccine.2011.07.063_bib0060) 1993; 67 Elliott (10.1016/j.vaccine.2011.07.063_bib0175) 2008; 82 Ito (10.1016/j.vaccine.2011.07.063_bib0220) 2006; 80 Wang (10.1016/j.vaccine.2011.07.063_bib0055) 2009; 6 Purcell (10.1016/j.vaccine.2011.07.063_bib0105) 2007; 6 Grange (10.1016/j.vaccine.2011.07.063_bib0195) 2008; 26 Tao (10.1016/j.vaccine.2011.07.063_bib0225) 2002; 160 Tamura (10.1016/j.vaccine.2011.07.063_bib0200) 1997; 278 Bollard (10.1016/j.vaccine.2011.07.063_bib0140) 2007; 110 Murray (10.1016/j.vaccine.2011.07.063_bib0150) 1998; 92 Walker (10.1016/j.vaccine.2011.07.063_bib0115) 2007; 7 Calderwood (10.1016/j.vaccine.2011.07.063_bib0215) 2006; 31 Wei (10.1016/j.vaccine.2011.07.063_bib0210) 2005; 365 Lin (10.1016/j.vaccine.2011.07.063_bib0100) 2002; 62 Rolland (10.1016/j.vaccine.2011.07.063_bib0170) 2005; 57 Wang (10.1016/j.vaccine.2011.07.063_bib0180) 2001; 22 Sun (10.1016/j.vaccine.2011.07.063_bib0035) 2004; 117 Straathof (10.1016/j.vaccine.2011.07.063_bib0090) 2005; 105 Lautscham (10.1016/j.vaccine.2011.07.063_bib0070) 2003; 77 Blachere (10.1016/j.vaccine.2011.07.063_bib0155) 1997; 186 Redchenko (10.1016/j.vaccine.2011.07.063_bib0135) 1999; 73 Meij (10.1016/j.vaccine.2011.07.063_bib0085) 2002; 99 Comoli (10.1016/j.vaccine.2011.07.063_bib0145) 2005; 23 Bollard (10.1016/j.vaccine.2011.07.063_bib0040) 2004; 27 Rickinson (10.1016/j.vaccine.2011.07.063_bib0050) 1997; 15 Chen (10.1016/j.vaccine.2011.07.063_bib0020) 2008; 5 Wong (10.1016/j.vaccine.2011.07.063_bib0190) 2008; 180 |
References_xml | – volume: 6 start-page: 404 year: 2007 end-page: 414 ident: bib0105 article-title: More than one reason to rethink the use of peptides in vaccine design publication-title: Nat Rev Drug Discov contributor: fullname: Rossjohn – volume: 180 start-page: 3122 year: 2008 end-page: 3131 ident: bib0190 article-title: Tumor-Specific CD4 publication-title: J Immunol contributor: fullname: Sherman – volume: 33 start-page: 441 year: 2006 end-page: 446 ident: bib0030 article-title: Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells publication-title: Auris Nasus Larynx contributor: fullname: Sun – volume: 62 start-page: 6952 year: 2002 end-page: 6958 ident: bib0100 article-title: Immunization with Epstein–Barr virus (EBV) peptide-pulsed dendritic cells induces functional CD8+T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma publication-title: Cancer Res contributor: fullname: Cheng – volume: 57 start-page: 669 year: 2005 end-page: 673 ident: bib0170 article-title: Gene medicines: the end of the beginning? publication-title: Adv Drug Delivery Rev contributor: fullname: Rolland – volume: 70 start-page: 5357 year: 1996 end-page: 5362 ident: bib0080 article-title: Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein–Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies publication-title: J Virol contributor: fullname: Silins – volume: 67 start-page: 7428 year: 1993 end-page: 7435 ident: bib0060 article-title: HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein–Barr virus isolates through a defined epitope in latent membrane protein LMP2 publication-title: J Virol contributor: fullname: Young – volume: 19 start-page: 3769 year: 2001 end-page: 3777 ident: bib0095 article-title: Contrasting Epstein–Barr virus-specific cytotoxic T cell responses to HLA A2-restricted epitopes in humans and HLA transgenic mice: implications for vaccine design publication-title: Vaccine contributor: fullname: Moss – volume: 27 start-page: 317 year: 2004 end-page: 327 ident: bib0040 article-title: The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease publication-title: J Immunother contributor: fullname: Davis – volume: 70 start-page: 1 year: 1997 end-page: 492 ident: bib0005 publication-title: Proceedings of the IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Epstein–Barr Virus and Kaposi's Sarcoma Herpesvirus/Human Herpesvirus 8 contributor: fullname: Cancer IAfRo – volume: 23 start-page: 8942 year: 2005 end-page: 8949 ident: bib0145 article-title: Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein–Barr virus-targeted cytotoxic T lymphocytes publication-title: J Clin Oncol contributor: fullname: Labirio – volume: 360 start-page: 436 year: 2002 end-page: 442 ident: bib0010 article-title: Treatment of Epstein–Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells publication-title: Lancet contributor: fullname: Iley – volume: 92 start-page: 2477 year: 1998 end-page: 2483 ident: bib0150 article-title: Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein–Barr virus-positive Hodgkin's disease publication-title: Blood contributor: fullname: Ambinder – volume: 14 start-page: 1013 year: 2007 end-page: 1023 ident: bib0120 article-title: Induction of CD4-independent E7-specific CD8 publication-title: Clin Vaccine Immunol contributor: fullname: Emtage – volume: 77 start-page: 2757 year: 2003 end-page: 2761 ident: bib0070 article-title: Identification of a TAP-independent, immunoproteasome-dependent CD8 publication-title: J Virol contributor: fullname: Leese – volume: 110 start-page: 2838 year: 2007 end-page: 2845 ident: bib0140 article-title: Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer publication-title: Blood contributor: fullname: Carrum – volume: 26 start-page: 955 year: 2008 end-page: 962 ident: bib0205 article-title: Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine publication-title: J Clin Oncol contributor: fullname: Camacho – volume: 52 start-page: 152 year: 2003 end-page: 154 ident: bib0045 article-title: Identification of latent membrane protein 2A (LMP2A) specific targets for treatment and eradication of Epstein–Barr virus (EBV)-associated diseases publication-title: J Antimicrob Chemother contributor: fullname: Portis – volume: 278 start-page: 117 year: 1997 end-page: 120 ident: bib0200 article-title: Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations publication-title: Science contributor: fullname: Srivastava – volume: 26 start-page: 4984 year: 2008 end-page: 4990 ident: bib0195 article-title: The use of mycobacterial adjuvant-based agents for immunotherapy of cancer publication-title: Vaccine contributor: fullname: Stanford – volume: 117 start-page: 1558 year: 2004 end-page: 1563 ident: bib0035 article-title: Induction of T-cell immunity against Epstein–Barr virus-associated tumors by means of adenovirally transduced dendritic cells publication-title: Chin Med J contributor: fullname: Zhou – volume: 31 start-page: 164 year: 2006 end-page: 172 ident: bib0215 article-title: Heat shock proteins in cancer: chaperones of tumorigenesis publication-title: Trends Biochem Sci contributor: fullname: Ciocca – volume: 5 start-page: 365 year: 2008 end-page: 372 ident: bib0020 article-title: Potent dendritic cell vaccine loaded with latent membrane protein 2A (LMP2A) publication-title: Cell Mol Immunol contributor: fullname: Liu – volume: 73 start-page: 334 year: 1999 end-page: 342 ident: bib0135 article-title: Accessing Epstein–Barr virus-specific T-cell memory with peptide-loaded dendritic cells publication-title: J Virol contributor: fullname: Rickinson – volume: 186 start-page: 1315 year: 1997 end-page: 1322 ident: bib0155 article-title: Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity publication-title: J Exp Med contributor: fullname: Basu – volume: 103 start-page: 1747 year: 2004 end-page: 1754 ident: bib0165 article-title: Novel heat shock protein Hsp70L1 activates dendritic cells and acts as a Th1 polarizing adjuvant publication-title: Blood contributor: fullname: Zhang – volume: 78 start-page: 768 year: 2004 end-page: 778 ident: bib0110 article-title: Dual stimulation of Epstein–Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma publication-title: J Virol contributor: fullname: Steven – volume: 282 start-page: 31688 year: 2007 end-page: 31702 ident: bib0160 article-title: Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling publication-title: J Biol Chem contributor: fullname: Brauchle – volume: 365 start-page: 2041 year: 2005 end-page: 2054 ident: bib0210 article-title: Nasopharyngeal carcinoma publication-title: Lancet contributor: fullname: Sham – volume: 15 start-page: 405 year: 1997 end-page: 431 ident: bib0050 article-title: Human cytotoxic T lymphocyte responses to Epstein–Barr virus infection publication-title: Annu Rev Immunol contributor: fullname: Moss – volume: 82 start-page: 1448 year: 2008 end-page: 1457 ident: bib0175 article-title: Phase I trial of a CD8 publication-title: J Virol contributor: fullname: Le – volume: 160 start-page: 1839 year: 2002 end-page: 1845 ident: bib0225 article-title: Conservation of Epstein–Barr virus cytotoxic T-cell epitopes in posttransplant lymphomas: implications for immune therapy publication-title: Am J Pathol contributor: fullname: Ambinder – volume: 99 start-page: 93 year: 2002 end-page: 99 ident: bib0085 article-title: Identification and prevalence of CD8(+) T-cell responses directed against Epstein–Barr virus-encoded latent membrane protein 1 and latent membrane protein 2 publication-title: Int J Cancer contributor: fullname: Bloemena – volume: 158 start-page: 3325 year: 1997 end-page: 3334 ident: bib0075 article-title: Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy publication-title: J Immunol contributor: fullname: Rickinson – volume: 7 start-page: 339 year: 2007 end-page: 350 ident: bib0115 article-title: Mycobacterial heat shock proteins as vaccines—a model of facilitated antigen presentation publication-title: Curr Mol Med contributor: fullname: Colaco – volume: 203 start-page: 696 year: 2004 end-page: 699 ident: bib0025 article-title: Expression of the Epstein–Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma publication-title: J Pathol contributor: fullname: Kremmer – volume: 9 start-page: 71 year: 2009 end-page: 78 ident: bib0185 article-title: CD4 publication-title: Expert Opin Biol Ther contributor: fullname: Peoples – volume: 191 start-page: 403 year: 2000 end-page: 408 ident: bib0125 article-title: In vivo cytotoxic T lymphocyte elicitation by mycobacterial heat shock protein 70 fusion proteins maps to a discrete domain and is CD4(+) T cell independent publication-title: J Exp Med contributor: fullname: Young – volume: 6 start-page: 423 year: 2009 end-page: 431 ident: bib0130 article-title: Immunotherapy of Epstein–Barr virus associated malignancies using mycobacterial HSP70 and LMP2A356-364 epitope fusion protein publication-title: Cell Mol Immunol contributor: fullname: Guo – volume: 345 start-page: 9 year: 1995 end-page: 13 ident: bib0015 article-title: Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr-virus-related lymphoproliferation publication-title: Lancet contributor: fullname: Krance – volume: 165 start-page: 573 year: 2000 end-page: 582 ident: bib0065 article-title: CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells publication-title: J Immunol contributor: fullname: Dawson – volume: 22 start-page: 269 year: 2001 end-page: 276 ident: bib0180 article-title: The role of MHC class II-restricted tumor antigens and CD4 publication-title: Trends Immunol contributor: fullname: Wang – volume: 6 start-page: 97 year: 2009 end-page: 103 ident: bib0055 article-title: Computational prediction and identification of Epstein–Barr virus latent membrane protein 2A antigen-specific CD8 publication-title: Cell Mol Immunol contributor: fullname: Chen – volume: 105 start-page: 1898 year: 2005 end-page: 1904 ident: bib0090 article-title: Treatment of nasopharyngeal carcinoma with Epstein–Barr virus-specific T lymphocytes publication-title: Blood contributor: fullname: Morriss – volume: 80 start-page: 883 year: 2006 end-page: 890 ident: bib0220 article-title: Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein–Barr virus LMP2A by overcoming specific structures resistant to epitope liberation publication-title: J Virol contributor: fullname: Tanimoto – volume: 52 start-page: 152 issue: August (2) year: 2003 ident: 10.1016/j.vaccine.2011.07.063_bib0045 article-title: Identification of latent membrane protein 2A (LMP2A) specific targets for treatment and eradication of Epstein–Barr virus (EBV)-associated diseases publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkg306 contributor: fullname: Swanson-Mungerson – volume: 31 start-page: 164 issue: 3 year: 2006 ident: 10.1016/j.vaccine.2011.07.063_bib0215 article-title: Heat shock proteins in cancer: chaperones of tumorigenesis publication-title: Trends Biochem Sci doi: 10.1016/j.tibs.2006.01.006 contributor: fullname: Calderwood – volume: 105 start-page: 1898 issue: March (5) year: 2005 ident: 10.1016/j.vaccine.2011.07.063_bib0090 article-title: Treatment of nasopharyngeal carcinoma with Epstein–Barr virus-specific T lymphocytes publication-title: Blood doi: 10.1182/blood-2004-07-2975 contributor: fullname: Straathof – volume: 23 start-page: 8942 issue: December (35) year: 2005 ident: 10.1016/j.vaccine.2011.07.063_bib0145 article-title: Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein–Barr virus-targeted cytotoxic T lymphocytes publication-title: J Clin Oncol doi: 10.1200/JCO.2005.02.6195 contributor: fullname: Comoli – volume: 117 start-page: 1558 issue: October (10) year: 2004 ident: 10.1016/j.vaccine.2011.07.063_bib0035 article-title: Induction of T-cell immunity against Epstein–Barr virus-associated tumors by means of adenovirally transduced dendritic cells publication-title: Chin Med J contributor: fullname: Sun – volume: 15 start-page: 405 year: 1997 ident: 10.1016/j.vaccine.2011.07.063_bib0050 article-title: Human cytotoxic T lymphocyte responses to Epstein–Barr virus infection publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.15.1.405 contributor: fullname: Rickinson – volume: 80 start-page: 883 issue: January (2) year: 2006 ident: 10.1016/j.vaccine.2011.07.063_bib0220 article-title: Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein–Barr virus LMP2A by overcoming specific structures resistant to epitope liberation publication-title: J Virol doi: 10.1128/JVI.80.2.883-890.2006 contributor: fullname: Ito – volume: 360 start-page: 436 issue: August (9331) year: 2002 ident: 10.1016/j.vaccine.2011.07.063_bib0010 article-title: Treatment of Epstein–Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells publication-title: Lancet doi: 10.1016/S0140-6736(02)09672-1 contributor: fullname: Haque – volume: 27 start-page: 317 issue: July–August (4) year: 2004 ident: 10.1016/j.vaccine.2011.07.063_bib0040 article-title: The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease publication-title: J Immunother doi: 10.1097/00002371-200407000-00008 contributor: fullname: Bollard – volume: 5 start-page: 365 issue: October (5) year: 2008 ident: 10.1016/j.vaccine.2011.07.063_bib0020 article-title: Potent dendritic cell vaccine loaded with latent membrane protein 2A (LMP2A) publication-title: Cell Mol Immunol doi: 10.1038/cmi.2008.45 contributor: fullname: Chen – volume: 186 start-page: 1315 issue: October (8) year: 1997 ident: 10.1016/j.vaccine.2011.07.063_bib0155 article-title: Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity publication-title: J Exp Med doi: 10.1084/jem.186.8.1315 contributor: fullname: Blachere – volume: 191 start-page: 403 issue: January (2) year: 2000 ident: 10.1016/j.vaccine.2011.07.063_bib0125 article-title: In vivo cytotoxic T lymphocyte elicitation by mycobacterial heat shock protein 70 fusion proteins maps to a discrete domain and is CD4(+) T cell independent publication-title: J Exp Med doi: 10.1084/jem.191.2.403 contributor: fullname: Huang – volume: 160 start-page: 1839 issue: May (5) year: 2002 ident: 10.1016/j.vaccine.2011.07.063_bib0225 article-title: Conservation of Epstein–Barr virus cytotoxic T-cell epitopes in posttransplant lymphomas: implications for immune therapy publication-title: Am J Pathol doi: 10.1016/S0002-9440(10)61130-3 contributor: fullname: Tao – volume: 165 start-page: 573 issue: July (1) year: 2000 ident: 10.1016/j.vaccine.2011.07.063_bib0065 article-title: CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells publication-title: J Immunol doi: 10.4049/jimmunol.165.1.573 contributor: fullname: Lee – volume: 62 start-page: 6952 issue: December (23) year: 2002 ident: 10.1016/j.vaccine.2011.07.063_bib0100 article-title: Immunization with Epstein–Barr virus (EBV) peptide-pulsed dendritic cells induces functional CD8+T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma publication-title: Cancer Res contributor: fullname: Lin – volume: 82 start-page: 1448 issue: February (3) year: 2008 ident: 10.1016/j.vaccine.2011.07.063_bib0175 article-title: Phase I trial of a CD8+T-cell peptide epitope-based vaccine for infectious mononucleosis publication-title: J Virol doi: 10.1128/JVI.01409-07 contributor: fullname: Elliott – volume: 6 start-page: 404 issue: May (5) year: 2007 ident: 10.1016/j.vaccine.2011.07.063_bib0105 article-title: More than one reason to rethink the use of peptides in vaccine design publication-title: Nat Rev Drug Discov doi: 10.1038/nrd2224 contributor: fullname: Purcell – volume: 110 start-page: 2838 issue: October (8) year: 2007 ident: 10.1016/j.vaccine.2011.07.063_bib0140 article-title: Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer publication-title: Blood doi: 10.1182/blood-2007-05-091280 contributor: fullname: Bollard – volume: 7 start-page: 339 issue: June (4) year: 2007 ident: 10.1016/j.vaccine.2011.07.063_bib0115 article-title: Mycobacterial heat shock proteins as vaccines—a model of facilitated antigen presentation publication-title: Curr Mol Med doi: 10.2174/156652407780831575 contributor: fullname: Walker – volume: 77 start-page: 2757 issue: February (4) year: 2003 ident: 10.1016/j.vaccine.2011.07.063_bib0070 article-title: Identification of a TAP-independent, immunoproteasome-dependent CD8+T-cell epitope in Epstein–Barr virus latent membrane protein 2 publication-title: J Virol doi: 10.1128/JVI.77.4.2757-2761.2003 contributor: fullname: Lautscham – volume: 282 start-page: 31688 issue: October (43) year: 2007 ident: 10.1016/j.vaccine.2011.07.063_bib0160 article-title: Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling publication-title: J Biol Chem doi: 10.1074/jbc.M704129200 contributor: fullname: Bendz – volume: 158 start-page: 3325 issue: April (7) year: 1997 ident: 10.1016/j.vaccine.2011.07.063_bib0075 article-title: Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy publication-title: J Immunol doi: 10.4049/jimmunol.158.7.3325 contributor: fullname: Lee – volume: 103 start-page: 1747 issue: March (5) year: 2004 ident: 10.1016/j.vaccine.2011.07.063_bib0165 article-title: Novel heat shock protein Hsp70L1 activates dendritic cells and acts as a Th1 polarizing adjuvant publication-title: Blood doi: 10.1182/blood-2003-08-2828 contributor: fullname: Wan – volume: 365 start-page: 2041 issue: June (9476) year: 2005 ident: 10.1016/j.vaccine.2011.07.063_bib0210 article-title: Nasopharyngeal carcinoma publication-title: Lancet doi: 10.1016/S0140-6736(05)66698-6 contributor: fullname: Wei – volume: 33 start-page: 441 issue: December (4) year: 2006 ident: 10.1016/j.vaccine.2011.07.063_bib0030 article-title: Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells publication-title: Auris Nasus Larynx doi: 10.1016/j.anl.2006.05.019 contributor: fullname: Xu – volume: 99 start-page: 93 issue: May (1) year: 2002 ident: 10.1016/j.vaccine.2011.07.063_bib0085 article-title: Identification and prevalence of CD8(+) T-cell responses directed against Epstein–Barr virus-encoded latent membrane protein 1 and latent membrane protein 2 publication-title: Int J Cancer doi: 10.1002/ijc.10309 contributor: fullname: Meij – volume: 203 start-page: 696 issue: June (2) year: 2004 ident: 10.1016/j.vaccine.2011.07.063_bib0025 article-title: Expression of the Epstein–Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma publication-title: J Pathol doi: 10.1002/path.1569 contributor: fullname: Heussinger – volume: 6 start-page: 97 issue: April (2) year: 2009 ident: 10.1016/j.vaccine.2011.07.063_bib0055 article-title: Computational prediction and identification of Epstein–Barr virus latent membrane protein 2A antigen-specific CD8+T-cell epitopes publication-title: Cell Mol Immunol doi: 10.1038/cmi.2009.13 contributor: fullname: Wang – volume: 26 start-page: 4984 issue: September (39) year: 2008 ident: 10.1016/j.vaccine.2011.07.063_bib0195 article-title: The use of mycobacterial adjuvant-based agents for immunotherapy of cancer publication-title: Vaccine doi: 10.1016/j.vaccine.2008.06.092 contributor: fullname: Grange – volume: 67 start-page: 7428 issue: December (12) year: 1993 ident: 10.1016/j.vaccine.2011.07.063_bib0060 article-title: HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein–Barr virus isolates through a defined epitope in latent membrane protein LMP2 publication-title: J Virol doi: 10.1128/JVI.67.12.7428-7435.1993 contributor: fullname: Lee – volume: 278 start-page: 117 issue: October (5335) year: 1997 ident: 10.1016/j.vaccine.2011.07.063_bib0200 article-title: Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations publication-title: Science doi: 10.1126/science.278.5335.117 contributor: fullname: Tamura – volume: 78 start-page: 768 issue: January (2) year: 2004 ident: 10.1016/j.vaccine.2011.07.063_bib0110 article-title: Dual stimulation of Epstein–Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma publication-title: J Virol doi: 10.1128/JVI.78.2.768-778.2004 contributor: fullname: Taylor – volume: 6 start-page: 423 issue: December (6) year: 2009 ident: 10.1016/j.vaccine.2011.07.063_bib0130 article-title: Immunotherapy of Epstein–Barr virus associated malignancies using mycobacterial HSP70 and LMP2A356-364 epitope fusion protein publication-title: Cell Mol Immunol doi: 10.1038/cmi.2009.54 contributor: fullname: Liu – volume: 26 start-page: 955 issue: February (6) year: 2008 ident: 10.1016/j.vaccine.2011.07.063_bib0205 article-title: Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group publication-title: J Clin Oncol doi: 10.1200/JCO.2007.11.9941 contributor: fullname: Testori – volume: 14 start-page: 1013 issue: August (8) year: 2007 ident: 10.1016/j.vaccine.2011.07.063_bib0120 article-title: Induction of CD4-independent E7-specific CD8+memory response by heat shock fusion protein publication-title: Clin Vaccine Immunol doi: 10.1128/CVI.00029-07 contributor: fullname: Liu – volume: 73 start-page: 334 issue: January (1) year: 1999 ident: 10.1016/j.vaccine.2011.07.063_bib0135 article-title: Accessing Epstein–Barr virus-specific T-cell memory with peptide-loaded dendritic cells publication-title: J Virol doi: 10.1128/JVI.73.1.334-342.1999 contributor: fullname: Redchenko – volume: 345 start-page: 9 issue: January (8941) year: 1995 ident: 10.1016/j.vaccine.2011.07.063_bib0015 article-title: Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr-virus-related lymphoproliferation publication-title: Lancet doi: 10.1016/S0140-6736(95)91150-2 contributor: fullname: Rooney – volume: 22 start-page: 269 issue: May (5) year: 2001 ident: 10.1016/j.vaccine.2011.07.063_bib0180 article-title: The role of MHC class II-restricted tumor antigens and CD4+T cells in antitumor immunity publication-title: Trends Immunol doi: 10.1016/S1471-4906(01)01896-8 contributor: fullname: Wang – volume: 19 start-page: 3769 issue: 27 year: 2001 ident: 10.1016/j.vaccine.2011.07.063_bib0095 article-title: Contrasting Epstein–Barr virus-specific cytotoxic T cell responses to HLA A2-restricted epitopes in humans and HLA transgenic mice: implications for vaccine design publication-title: Vaccine doi: 10.1016/S0264-410X(01)00085-8 contributor: fullname: Bharadwaj – volume: 180 start-page: 3122 issue: March (5) year: 2008 ident: 10.1016/j.vaccine.2011.07.063_bib0190 article-title: Tumor-Specific CD4+T cells render the tumor environment permissive for infiltration by low-avidity CD8+T cells publication-title: J Immunol doi: 10.4049/jimmunol.180.5.3122 contributor: fullname: Wong – volume: 57 start-page: 669 issue: 5 year: 2005 ident: 10.1016/j.vaccine.2011.07.063_bib0170 article-title: Gene medicines: the end of the beginning? publication-title: Adv Drug Delivery Rev doi: 10.1016/j.addr.2005.01.002 contributor: fullname: Rolland – volume: 92 start-page: 2477 issue: October (7) year: 1998 ident: 10.1016/j.vaccine.2011.07.063_bib0150 article-title: Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein–Barr virus-positive Hodgkin's disease publication-title: Blood doi: 10.1182/blood.V92.7.2477 contributor: fullname: Murray – volume: 70 start-page: 1 year: 1997 ident: 10.1016/j.vaccine.2011.07.063_bib0005 publication-title: IARC Monogr Eval Carcinog Risks Hum contributor: fullname: Cancer IAfRo – volume: 9 start-page: 71 issue: January (1) year: 2009 ident: 10.1016/j.vaccine.2011.07.063_bib0185 article-title: CD4+T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37) publication-title: Expert Opin Biol Ther doi: 10.1517/14712590802614538 contributor: fullname: Mittendorf – volume: 70 start-page: 5357 issue: August (8) year: 1996 ident: 10.1016/j.vaccine.2011.07.063_bib0080 article-title: Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein–Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies publication-title: J Virol doi: 10.1128/JVI.70.8.5357-5362.1996 contributor: fullname: Khanna |
SSID | ssj0005319 |
Score | 2.0988166 |
Snippet | Abstract Epstein–Barr virus (EBV) latent membrane protein 2A (LMP2A) is a subdominant antigen expressed in EBV-associated malignancies, such as Hodgkin's... Epstein–Barr virus (EBV) latent membrane protein 2A (LMP2A) is a subdominant antigen expressed in EBV-associated malignancies, such as Hodgkin's diseases (HD)... Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A) is a subdominant antigen expressed in EBV-associated malignancies, such as Hodgkin's diseases (HD)... |
SourceID | proquest crossref pubmed pascalfrancis fao elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 7414 |
SubjectTerms | Adjuvant Adjuvants Allergy and Immunology Animal models Animals antigens Antigens, Bacterial - immunology Applied microbiology Bacteriology Biological and medical sciences Cancer Cancer Vaccines - immunology Carcinoma Chaperones Clinical trials cytotoxic T-lymphocytes Cytotoxicity Cytotoxicity, Immunologic Epstein-Barr virus Fundamental and applied biological sciences. Psychology genetically modified organisms Heat shock protein 70 Herpes viruses Herpesvirus 4, Human - immunology Histocompatibility antigen HLA Hodgkin disease Hodgkin Disease - immunology Hodgkin's disease HSP70 Heat-Shock Proteins - immunology Hsp70 protein Human herpesvirus 4 Humans Immune response Immunity Immunotherapy Interferon-gamma - biosynthesis Latent membrane protein 2A LMP2A protein Lymphocytes Lymphocytes T Malignancy Melanoma Membrane proteins Mice Mice, Transgenic Microbiology Miscellaneous Multiprotein Complexes - immunology Mycobacterium tuberculosis Mycobacterium tuberculosis - immunology Nasopharyngeal Carcinoma Nasopharyngeal Neoplasms - immunology Peptides Plasmids Protein folding Studies T-Lymphocytes, Cytotoxic - immunology T-Lymphocytes, Cytotoxic - metabolism Transgenic mice Tuberculosis Tumors Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Viral Matrix Proteins - immunology Viral Vaccines - immunology Virology |
SummonAdditionalLinks | – databaseName: Elsevier ScienceDirect Freedom Collection dbid: AIKHN link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb5swFLbaVJv2Mm3ZpWxd5YepT6UxBox5zKpW2SVVpCRV3iwb7ClVG6JAqvJn9lt3zCWomrpJe0uAgw18nHOMv_MZoc-ppyKtQt-VLA7cgKXEVVYZUYWeVSvzTMRsgfP4io3mwbdFuNhD520tjKVVNr6_9umVt262DJq7OVgvl4MpqWI5WUAAs1z2xT46gHBEeQ8dDL9-H111TA-_Wt_DHu9ag66QZ3Bzdi8TO4PdiHlGZ4T5T4WofSMzy52UOdw-U6978XRiWgWoy1foZZNZ4mHd-ddoT6_66Fm91mTZR8_HzSx6H51Mar3q8hTPuvKr_BSf4EmnZA02_WtLlqkqdnFr_gb9skPWlmOQ4oqUrh90jjOD78oEHEQlAA19GU0nEcFyleKLL9f4x3hCh24Ku-7BbG3pNClY6Vs4b9H-d23pp6Uv4aQssiJ7gF8zfFsC6DLYovGmJvWCoT0v4GLpFtu7bIOXVaVLUb5F88uL2fnIbZZ5cBPINQvXaEs2VVZLD9ItHmrOEquqTxM_5UYHvvaJhIG0R40xmsWelLGODTVRKCHDMP471FtlK32IsITRk0qJr4iiQUISldCUcOMnJmapiZWDztonK9a1modoaW43ooGCsFAQJBIABQdF7fMXbakqOFedN296LjyRU0HEH2h0EN9ZPgK0gFj1r0YPAWlC_gQ3L-ZTaj9KwS2C2BI66PgR_HZXQQPGGeOxg45aPIquj0HMCQwcSeQgvNsNfsRODsmVzra54OCJIdv2_3pIbBUrGTTyvkZ617zHIXaEwYf_v-qP6AVt-ZXsCPWKzVZ_goSvUMfNC_0b79xUOw priority: 102 providerName: Elsevier |
Title | Reconstituted complexes of mycobacterial HSP70 and EBV LMP2A-derived peptides elicit peptide-specific cytotoxic T lymphocyte responses and anti-tumor immunity |
URI | https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X1101108X https://dx.doi.org/10.1016/j.vaccine.2011.07.063 https://www.ncbi.nlm.nih.gov/pubmed/21807054 https://www.proquest.com/docview/1498097407 https://search.proquest.com/docview/896395137 https://search.proquest.com/docview/899138269 |
Volume | 29 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9NAEF6RViAuCAK0hhLtAfVUp-vX2j6htEoVHokiklS-rdb2LmrVxiF2qvrCT-G3MuNHAoeWSxLHGe_Gnp35dvebGUI-plbsq9hzTMlD13R5yswYMyPGnoXZyiztcwxwHk_4aOF-ibyoWXDLG1plaxMrQ51mCa6RnwKSDxiAX-Z_Wv00sWoU7q42JTQ6ZN8CP4eUvuD8L4qHUxX2gGkGdMNi0S6C5_S6fycT3Lpusnj6fcadh3xTR8sMSZMyh_um64IXDyPSyjNdvCQvGkhJB7UOvCJP1LJLntZFJssueTZuts-75HhaJ6ouT-h8F3eVn9BjOt2lsAaZ7iWyZKpQXdqKvya_ca7akgtSWrHR1b3KaabpbZmAZagyP0NfRrOpz6hcpnR4dkm_jaf2wEzh1B2IrZBHk4KUuoHrFu2xiTGfyFuiSVlkRXYPn-b0pgRty-AbRdc1mxcE8bqgEFdmsbnN1vSqCnEpyjdkcTGcn4_Mpr6DmQDILEytkGUaYxI9wFmBpwKeYDp9O3HSQCvXUQ6TMIO2bK214qElZahCbWvfkwAttPOW7C2zpTokVMK0KU6ZE7PYdhOWxImdskA7iQ55qsPYIP32yYpVncZDtPy2a9GogkBVEMwXoAoG8dvnL9oYVbCqKm-GeC4skduCiRmrICWLAEdhSEVkkGAr2aCYGp0IcFL_a_QQNE3IH2DfxWJm42oU3CJwKp5Bev-o3_Zf2C4POA9Cgxy1-ih2fdwOGoPQ7WkwILgrJJcq2-QiABMMMNt59Cchpqrk0MhBrem75q0AnIbnvnu8-ffkud2SJ_kR2SvWG_UB0FwR90in_8uCVz_ye9Xw7ZH9weevowm8nw0n0-9_AMfJTYs |
link.rule.ids | 315,783,787,4509,12068,12235,21400,24128,27936,27937,31731,31732,33278,33279,33756,33757,43322,43591,43817,45597,45691,74073,74342,74630 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1bb9MwFLbYEJcXBOWywBh-QHtaOufmJE9ooE0F2qlS2ylvlhPbaNPWlCadlj_Db-WcXBrxsPHWNj2xk5wcf7a_8x1CPisnDXUaeLbksW_7XDE7RWXENHBQrcwxIccE58k5Hy38H0mQtAtuRUur7GJiHahVnuEa-TEg-YgB-GXhl9VvG6tG4e5qW0JjhzxGHS6sYBAmYU_x8OrCHjDNgG44LOkzeI6vhrcyw63rVsUzHDLu3Tc27RiZI2lSFnDfTFPw4n5EWo9MZy_JixZS0pPGB16RR3o5IE-aIpPVgDydtNvnA3I4bYSqqyM67_OuiiN6SKe9hDXYDC6QJVOn6tLO_DX5g3PVjlygaM1G13e6oLmhN1UGkaFWfoa-jGbTkFG5VPT06wUdT6buia3g0C2YrZBHo8BKX8N5y-67jTmfyFuiWVXmZX4Hn-b0ugJvy-EXTdcNmxcM8bzgEJd2ubnJ1_SyTnEpqzdkcXY6_zay2_oOdgYgs7SNRpZpiiJ6gLOiQEc8Qzl9N_NUZLTvaY9JmEE7rjFG89iRMtaxcU0YSIAWxntLdpf5Uu8RKmHalCrmpSx1_YxlaeYqFhkvMzFXJk4tMuyerFg1Mh6i47ddidYVBLqCYKEAV7BI2D1_0eWoQlTVRfuKF8IRhSuYmLEaUrIEcBSmVCQWibaWLYpp0ImAQep_je6Bpwn5C-K7WMxcXI2CWwSDSmCRg3_cb3sVrs8jzqPYIvudP4q-j9uXxiJ0exgCCO4KyaXON4WIIAQDzPYe_EuMUpUcGnnXeHrfvBPBoBH47x9u_hN5NppPxmL8_fznB_Lc7YiUfJ_sluuN_gjIrkwP6tf3L4baS50 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Nb9NAEF3RIiouCAK0hlL2gHqqk_XX2j6hAo0CNFWkJJVvq7W9i1q1doidqv4z_FZm_BGLQ8stiT3ejf129q33zQwhn1Ir9lXsOabkoWu6PGVmjJkRY8_CbGWW9jkGOE8v-GTp_oi8qNU_Fa2ssvOJtaNO8wTfkY-AyQcMyC_zR7qVRcy-jT-vfptYQQp3WttyGjvkKZ6FmPcjv5d7OHWRD1hyQJcsFvXRPKPr4Z1McBu7zejpDxl3HpqndrTMUUApC7iHuil-8TA7rWep8UvyoqWX9LTBwyvyRGUD8qwpOFkNyN603UofkONZk7S6OqGLPgarOKHHdNanswabwSUqZuqwXdqZvyZ_cN3aCQ1SWivT1b0qaK7pbZWAl6izQENfJvOZz6jMUnr25ZKeT2f2qZnCoTswW6GmJgUrdQPXLbvvJsZ_ooaJJlWZl_k9fFrQmwqQl8Mviq4bZS8Y4nUBHFdmubnN1_SqDncpqzdkOT5bfJ2Yba0HMwHCWZpaoeI0xoR6wLkCTwU8wdT6duKkgVauoxwmYTVt2VprxUNLylCF2ta-J4FmaOct2c3yTB0QKmEJFafMiVlsuwlL4sROWaCdRIc81WFskGH3ZMWqSekhOq3btWihIBAKgvkCoGAQv3v-ootXBQ-rina4F8IShS2YmLOaXrIIOBWGV0QGCbaWLaNpmIqACet_jR4A0oT8Bb5eLOc2vpmCWwQTjGeQo3_gt_0XtssDzoPQIIcdHkXfx-0AMgjdHgZngjtEMlP5phABuGOg3M6jp4SYtpJDI_sN0vvmrQAmEM9993jzH8kejFxx_v3i53vy3O40lfyQ7JbrjfoAJK-Mj-rR-xdT5E_V |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reconstituted+complexes+of+mycobacterial+HSP70+and+EBV+LMP2A-derived+peptides+elicit+peptide-specific+cytotoxic+T+lymphocyte+responses+and+anti-tumor+immunity&rft.jtitle=Vaccine&rft.au=Liu%2C+Genyan&rft.au=Yao%2C+Kun&rft.au=Wang%2C+Bing&rft.au=Zhou%2C+Feng&rft.date=2011-10-06&rft.issn=0264-410X&rft.volume=29&rft.issue=43&rft.spage=7414&rft.epage=7423&rft_id=info:doi/10.1016%2Fj.vaccine.2011.07.063&rft.externalDBID=NO_FULL_TEXT |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X11X00415%2Fcov150h.gif |